We've updated our Privacy Policy to make it clearer how we use your personal data. We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Therapeutic Protein Development, Protein Expression System, Gene Expression Technology, Biopharmaceutical Manufacturing, Protein Discovery to Commercialization, Therapeutic Protein Production, Gene Expression for Biologics, Bioprocessing Solutions, GS Gene Expression System, Protein Therapeutics, Commercial-Scale Protein Production, Protein Expression Platform, Biopharma Gene Expression, High-Yield Protein Production, Biotherapeutic Development
Credit: Getty Images

Product
Advertisement

GS Gene Expression System®: Taking Your Therapeutic Protein from Discovery to Commercial

GS Gene Expression System®: Taking Your Therapeutic Protein from Discovery to Commercial
Credit: Getty Images


A fully integrated toolbox for therapeutic protein expression, Lonza’s GS Gene Expression System has been successfully used to express a wide range of molecules, from monoclonal antibodies to bispecifics to fusion proteins and beyond to titres up to 9 g/L. With our Lonza in Your Lab® offering, you have the flexibility to either take our technologies into your lab under license, or let Lonza do the work for you, at any stage in the process. With either option, our dedicated team of experts are here to support you and maximise your success.


Integrated

The integrated GS® toolbox of cell lines, vectors, technologies, media systems and know-how enable optimal gene expression and cell line development, expediting potentially life-saving biologic therapeutics to the clinic, and to patients in need.


Stable and Scalable Cell Lines

The GS Xceed® CHOK1SV GS-KO® host cell line is familiar to regulators and has proven performance. GS Xceed® drives high titers across a range of molecular formats. GS Effex® is the latest plug and play addition to the GS® toolbox. Derived from the leading GS Xceed® cell line, GS Effex® produces antibodies that are 100% free of fucose and have increased potency, without compromising on the titers, growth, stability and product quality that GS Xceed® is known for.


Boost Expression with GS piggyBac® Transposase

Lonza has exclusive human therapeutic rights for GS piggyBac® transposon technology. By preferentially targeting regions of the genome associated with stable, highly expressed genes, GS piggyBac® boosts gene expression. GS piggyBac® generates cell lines that are able to produce high yields with reliability and consistency, which is ideal for new molecular formats that can be difficult to express. Furthermore, GS piggyBac® enables fast stable pool generation, delivering high quality and highly representative pool material to bridge new biologics from discovery into clinical development.


Versatile, efficient GSquad® vectors

New molecular formats such as such as bispecific antibodies and fusion proteins require the expression of multiple genes. Lonza’s GSquad® vector system makes it simpler to create a GS piggyBac® expression vector that encodes for up to four product genes. With speed and reliability in mind, a rapid two-step vector construction process is effective for both simple proteins and proteins that are novel in design or difficult to express.


Innovative

Built on over 35 years of continual development, our dedicated R&D teams ensure that the GS System® keeps pace with evolving industry demands. In 2023 alone, we launched 3 upgrades to the system with more on the horizon.


Recent launches:

-The GS Effex® cell line for the production of mAbs with increased potency without compromising on performance

-GS Discovery® CHO transient expression platform which enables high titre transient expression, and the use of the same cell line, vectors and technologies from discovery through to commercial supply

-The TheraPRO® CHO Media System, our scalable, easy-to-use, optimised media system that can shorten time to market


Trusted

Having enabled the expression of over 80 commercial products, the GS Gene Expression System® has a long, proven track record of product success and is familiar to regulators, minimizing diligence and compliance-related costs and delays. Coupled with Lonza’s expertise and ongoing support, the platform de-risks the partnering process to give confidence and peace of mind.


About Lonza
Lonza is a healthcare manufacturing organization helping pharmaceutical, biotech and nutrition companies to bring their treatments to market. They help their customers to deliver new and innovative medicines that treat a wide range of diseases, allowing their patients to benefit from life-saving and life-enhancing treatments.
Interested in seeing more content from Lonza?
Discover all their latest news, webinars, products and more by clicking the link below.